{
    "id": 7146,
    "fullName": "MAPK3 C82Y",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "MAPK3 C82Y lies within the protein kinase domain of the Mapk3 protein (UniProt.org). C82Y has been described as a drug resistance mutation (PMID: 25320010), but has not been biochemically characterized and therefore, its effect on Mapk3 protein function is unknown (PubMed, Jul 2018).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5595,
        "geneSymbol": "MAPK3",
        "terms": [
            "MAPK3",
            "ERK-1",
            "ERK1",
            "ERT2",
            "HS44KDAP",
            "HUMKER1A",
            "p44-ERK1",
            "p44-MAPK",
            "P44ERK1",
            "P44MAPK",
            "PRKM3"
        ]
    },
    "variant": "C82Y",
    "createDate": "06/06/2015",
    "updateDate": "07/01/2018",
    "referenceTranscriptCoordinates": {
        "id": 162296,
        "transcript": "NM_002746",
        "gDna": "chr16:g.30121932C>T",
        "cDna": "c.245G>A",
        "protein": "p.C82Y",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2340,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK3 C82Y demonstrated resistance to SCH772984 in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 7013,
                "profileName": "MAPK3 C82Y"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2339,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK3 C82Y demonstrated resistance to VX-11e in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 7013,
                "profileName": "MAPK3 C82Y"
            },
            "therapy": {
                "id": 2804,
                "therapyName": "VX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 7013,
            "profileName": "MAPK3 C82Y",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 162297,
            "transcript": "NM_001040056",
            "gDna": "chr16:g.30121932C>T",
            "cDna": "c.245G>A",
            "protein": "p.C82Y",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 162296,
            "transcript": "NM_002746",
            "gDna": "chr16:g.30121932C>T",
            "cDna": "c.245G>A",
            "protein": "p.C82Y",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 162295,
            "transcript": "NM_001109891",
            "gDna": "chr16:g.30121932C>T",
            "cDna": "c.245G>A",
            "protein": "p.C82Y",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}